Avenue Therapeutics reports Q3 net income of $0.5M; cash low, raises $5M

AVENUE THERAPEUTICS, INC.

2023-Q3 EPS reported -$1.54

Net income $0.5M ($0.06 per share) vs net loss $0.7M in Q3 2022; R&D $0.9M, G&A $1.2M.
Cash $0.2M at Sep 30, 2023; completed $5M public equity offering in Nov 2023.
AJ201 Phase 1b/2a enrollment on track; topline data expected Q2 2024.
BAER-101 preclinical results accepted for AES meeting; IV tramadol Phase 3 design agreed with FDA.
IV tramadol Phase 3 safety study pending additional financing; aim to start as soon as feasible.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

AVENUE THERAPEUTICS, INC. reported the third quarter ended September 30, 2023 results: net income Net income attributable to common stockholders for the third quarter of 2023 was $0.5 million, or $0.06 per share, EPS $0.06 per share.

Period: the third quarter ended September 30, 2023
Net income: Net income attributable to common stockholders for the third quarter of 2023 was $0.5 million, or $0.06 per share
EPS: $0.06 per share
Result: reported results

Exact text from the filing

On November 13, 2023, Avenue Therapeutics, Inc. (the “Company” or “Avenue”) issued a press release to provide a corporate update and to announce its financial results for the three months ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

AVENUE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-031615

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.